Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
28.46
+0.05 (0.18%)
At close: Dec 5, 2025, 4:00 PM EST
28.50
+0.04 (0.14%)
After-hours: Dec 5, 2025, 7:58 PM EST
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 27, with a low estimate of 22 and a high estimate of 35. The average target predicts a decrease of -5.13% from the current stock price of 28.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +22.98% | Dec 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $26 → $28 | Buy | Maintains | $26 → $28 | -1.62% | Nov 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $23 → $26 | Buy | Maintains | $23 → $26 | -8.64% | Oct 3, 2025 |
| UBS | UBS | Strong Buy Maintains $23 → $26 | Strong Buy | Maintains | $23 → $26 | -8.64% | Sep 24, 2025 |
| UBS | UBS | Strong Buy Maintains $24 → $23 | Strong Buy | Maintains | $24 → $23 | -19.18% | Jun 26, 2025 |
Financial Forecast
Revenue This Year
17.33B
from 16.54B
Increased by 4.74%
Revenue Next Year
17.41B
from 17.33B
Increased by 0.48%
EPS This Year
2.70
from -1.45
EPS Next Year
2.80
from 2.70
Increased by 3.95%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 18.0B | 18.2B | |
| Avg | 17.3B | 17.4B | |
| Low | 16.5B | 16.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 9.0% | 4.8% | |
| Avg | 4.7% | 0.5% | |
| Low | -0.0% | -4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.88 | 2.99 | |
| Avg | 2.70 | 2.80 | |
| Low | 2.54 | 2.63 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 11.0% | |
| Avg | - | 4.0% | |
| Low | - | -2.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.